EPISODE · Jun 27, 2025 · 20 MIN
ArsenalBio's Co-Founder & CEO Ken Drazan talks about engineering the next generation of T-cell therapies, including a clinical stage renal cell program that includes multiple features
from BiotechTV - News · host BiotechTV
He describes the ArsenalBio's "CITE" platform, which allows it to make heterogenous cells by inserting modifications all in the same place. Plus, writing in logic gating, harnessing shRNA, and more. The company recently raised a $325M series C.
What this episode covers
He describes the ArsenalBio's "CITE" platform, which allows it to make heterogenous cells by inserting modifications all in the same place. Plus, writing in logic gating, harnessing shRNA, and more. The company recently raised a $325M series C.
NOW PLAYING
ArsenalBio's Co-Founder & CEO Ken Drazan talks about engineering the next generation of T-cell therapies, including a clinical stage renal cell program that includes multiple features
No transcript for this episode yet
Similar Episodes
Apr 21, 2026 ·13m
Apr 19, 2026 ·16m
Apr 17, 2026 ·13m
Apr 13, 2026 ·11m
Apr 11, 2026 ·16m